CDK9 targeting PROTAC L055 inhibits ERα-positive breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Breast cancer remains a leading cause of mortality in women globally.
• Existing treatments necessitate the development of more targeted and effective therapeutic strategies.
• Proteolysis-targeting chimeras (PROTACs) offer a novel approach for targeted protein degradation.

Purpose of the Study:

• To design, synthesize, and evaluate a novel CRBN-based PROTAC, L055, targeting CDK9.
• To assess the efficacy of L055 in inhibiting proliferation and inducing apoptosis in ERα-positive breast cancer cells.
• To investigate the therapeutic potential of L055 in preclinical models of breast cancer.

Main Methods:

• Synthesis and characterization of the CRBN-based PROTAC, L055.
• In vitro assays to evaluate L055's effects on cell proliferation, cell cycle, and apoptosis.
• In vivo studies using organoid and xenograft models in nude mice to assess tumor growth suppression.

Main Results:

• L055 demonstrated potent inhibition of proliferation and induction of cell cycle arrest in ERα-positive breast cancer cells.
• L055 specifically induced the degradation of CDK9 through the CRBN-dependent proteasomal pathway.
• In vivo studies showed that L055 suppressed the growth of breast cancer organoids and tumors.

Conclusions:

• L055 is a potent CDK9 degrader with significant therapeutic potential for ERα-positive breast cancer.
• The CRBN-based PROTAC strategy shows promise for developing novel cancer therapies.
• L055 may represent a new therapeutic avenue for breast cancer and other cancers driven by specific oncoproteins.